Risk Factors Associated with Heart Valve Thrombosis in Patients with Prosthetic Heart Valve Dysfunction

Abstract

Background: Thrombotic and thromboembolic events are important causes of mortality and morbidity in patients with prosthetic heart valve. The aim of this study is to evaluate the factors that may contribute to prosthetic heart valve thrombosis. Methods: This was a cross-sectional study in Rajaie Heart Center on patients with prosthetic heart valve malfunction, within a year. According to the echocardiographic and fluoroscopic findings, the patients were divided into two groups (thrombosis and non-thrombosis groups). The patients’ demographic, clinical and laboratory data were recorded and analyzed with SPSS software. Results: A total of 142 patients participated in this study. Ninety-four patients (66.2%) were diagnosed with thrombosis. There was a significant relationship between thrombosis and inadequate anti-coagulation (international normalized rati [INR] <2.5) (odds ratio [OR]: 4.15, 95% CI: 1.98-9.87, P = 0.003), history of infection (OR: 12.81, 95% CI: 3.52-19.02, P<0.001), prothrombin time (PT) check interval (OR: 2.38, 95% CI: 1.63-8.47, P = 0.019), atrial fibrillation (AF) rhythm (OR: 3.96, 95% CI: 1.75-8.09, P = 0.019), and plasma fibrinogen level (OR: 6.90, 95% CI: 2.58-14.69). Conclusion: Based on this study, inadequate anti-coagulation, AF rhythm, recent infection and plasma fibrinogen level were the factors most contributing to prosthetic valve thrombosis. As there were many cases of thrombosis in patients with history of infection, this factor can be considered for risk assessment in prosthetic valve.

Comprehensive collection of COVID-19 related prosthetic valve failure: a systematic review

“…In general, mechanical valve PVT is generally more prevalent compared with bioprosthetic valve PVT [ 22 , 23 ], with thrombosis incidence rate being 3–190 times greater for mechanical valves (0.1–5.7%) than for bioprosthetic valves (0.03%) [ 23 ]. For the eight cases in this review, the number of PVT incidents involving mechanical valves vs bioprosthetic valves were equal.…”

Circulating Levels of Calprotectin as a Biomarker in Patients With Coronary Artery Disease: A Systematic Review and Meta‐Analysis

“…Coronary artery disease (CAD) is characterized by atherosclerosis in coronary arteries [ 1 ], and CAD‐related mortality has been predicted to increase through 2030 [ 1 , 2 ]. This condition puts a substantial medical and economic burden on families and healthcare systems [ 3 , 4 , 5 ]. Despite the improvement in the prognosis of CAD patients, the prevalence of CAD remains high due to worsening cardiovascular risk factors [ 6 , 7 , 8 ].…”